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The northern treeshrew (Tupaia belangeri) has been reported to be an effective candidate for animal
infection model with hepatitis B virus (HBV). The objective of our study was to analyze the growth
characteristics of HBV in tupaia hepatocytes and the host response to HBV infection. We established
primary tupaia hepatocytes (3e6-week old tupaia) and infected them with HBV genotypes A, B and C,
and all the genotypes proliferated as well as those in human primary hepatocytes (>105 copies/ml in
culture supernatant). We next generated a chimeric mouse with tupaia liver by transplantation of tupaia
primary hepatocytes to urokinase-type plasminogen activator cDNA (cDNA-uPA)/severe combined
immunodeﬁcient (SCID) mice and the replacement ratio with tupaia hepatocytes was found to be more
than 95%. Infection of chimeric mice with HBV (genotypes B, C, and D) resulted in HBV-DNA level of 104-
106 copies/ml after 8 weeks of infection, which were almost similar to that in humanized chimeric
mouse. In contrast, serum HBV level in adult tupaia (1-year-old tupaia) was quite low (<103 copies/ml).
Understanding the differences in the response to HBV infection in primary tupaia hepatocytes, chimeric
mouse, and adult tupaia will contribute to elucidating the mechanism of persistent HBV infection and
viral eradication. Thus, T. belangeri was found to be efﬁcient for studying the host response to HBV
infection, thereby providing novel insight into the pathogenesis of HBV.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis B virus (HBV), a member of the family Hepadnaviridae,
causes acute and chronic hepatitis, which is one of the major healthogy and Cell Biology, Tokyo
kitazawa, Setagaya-ku, Tokyo
eases Centre, Joint Faculty of
, Korimoto, Kagoshima-city,
.jp (K. Tsukiyama-Kohara),
Inc. This is an open access article uconcerns in the world. Chronic HBV infection is strongly associated
with an increased risk of cirrhosis, which in turn leads to hepato-
cellular carcinoma [1,2]. Worldwide, 2 billion people have been
reported to be infected with HBV, and more than 350 million have
been reported with chronic infection [3].
Currently, clinically available HBV drugs are nucleoside or
nucleotide analogs that inhibit the viral reverse transcriptase (RT),
but these drugs have recently been reported to result in viral
resistance [4]. Moreover, RT inhibitors only control HBV replication,
and cannot cure HBV infection completely. One factor that impedes
the development of therapy for HBV elimination is the lack of a
suitable animal model to study HBV pathogenesis. To date, the
chimpanzee is the only existing natural infection animal model, butnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stringent animal welfare regulations, it is difﬁcult to use it [5].
Northern treeshrew (Tupaia belangeri), which belongs to the
family Tupaiidae, is a small mammal that has a body weight of
about 100e150 g, and it is genetically close to primates [5,6]. Tupaia
is susceptible to hepatitis viruses such as HBV and hepatitis C virus
(HCV) [7,8]. Since HBV causes hepatitis and persistent infection in
tupaia like that in humans, it could be used as an animal model for
studying HBV infection. However, the infection mode in tupaia and
the host response to HBV infection is unknown.
Chimeric urokinase-type plasminogen activator transgenic
(uPA)/severe combined immunodeﬁcient (SCID) mice with hu-
manized liver [9] are immune-deﬁcient and thus are suitable hosts
for HBV infection within hepatocytes [10,11]. To expand the po-
tential of the tupaia animal model for the characterization of HBV
growth, we established chimeric mice with tupaia hepatocytes
based on urokinase-type plasminogen activator cDNA (cDNA-uPA)/
SCID mouse in this study, and assessed the HBV propagation in
primary tupaia hepatocytes, chimeric mouse with tupaia hepato-
cytes, and adult tupaia.
2. Materials and methods
2.1. Ethics statement
This study was carried out in strict accordance with the Guide-
lines for Animal Experimentation of the Japanese Association for
Laboratory Animal Science and the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes
of Health. All protocols were approved by the regional ethics
committee.
2.2. Animals
Northern treeshrews (T. belangeri) were purchased from
Kunming Institute of Zoology, Chinese Academy of Sciences.
2.3. HBV inocula
The HBV inoculum was the serum of chimeric mouse with hu-
manized liver infected with HBV genotype A (A2_JP1, A2_JP2,
A2_JP4; now submitting to GENBANK), B (Bj_JPN35; accession
number: AB246341.1), C (C_JPNAT; accession number:
AB246345.1), D (D3_MR1; now submitting to GENBANK), or J
(JRB34; accession number: AB486012.1).
2.4. Isolation and culture of primary tupaia hepatocytes
Tupaia hepatocytes (tupaia hepatocytes #1 and #2) were iso-
lated using a two-step collagenase perfusion method which was
modiﬁed based on a previously described method [12] (Fig. 1A).
Tupaia (3e6 weeks old) liver was perfused at 38 C for 7 min at
3 ml/min with Hank's balanced salt solution (HBSS) supplemented
with 1 mg/ml D-glucose, 200 mg/ml ethylene glycol tetraacetic acid,
10 mg/ml gentamicin, and 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES). The liver was then
perfused at 37 C for 11.5e16min at 3 ml/minwith HBSS containing
0.05% type IV collagenase (Sigma Aldrich, St. Louis, MO, USA),
140 mg/ml CaCl2, 10 mg/ml gentamicin,10mMHEPES, and 100 mg/ml
trypsin inhibitor. The perfused liver was separated and dis-
aggregated with maintenance medium as Dulbecco's modiﬁed
Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-
glutamine, 100 U/ml penicillin G, and 100 mg/ml streptomycin,
44 mM NaHCO3. The disaggregated cells were collected and
centrifuged at 50 g for 2min thrice. The cell pellet was suspendedin the maintenance medium and cultured on a collagen-coated 48-
well plate with 2.0  105 cells/well.
2.5. HBV infection in primary tupaia and human hepatocytes
Primary human hepatocytes (PXB-cells) were purchased from
PhoenixBio (Hiroshima, Japan). Primary tupaia and human hepa-
tocytes were infected with HBV at 5-genome equivalents/cell with
4% polyethylene glycol 8000 (Promega, Madison,WI, USA). At 1 and
2 days postinoculation (dpi), the inoculated cells were washed, and
the culture supernatant was collected every 5 days.
2.6. HBV-DNA quantiﬁcation
Viral DNA from serum or culture supernatant was extracted
using SMItest EX-R&D kits (Nippon Genetics Co., Ltd., Tokyo, Japan)
according to the manufacturer's instructions. HBV-DNA was
quantiﬁed by real-time detection PCR, as previously described [13].
The primers and probes for the S gene consisted of a forward
primer HB-166-S21 (nts 166e186): 50-CACATCAGGATTCCTAG-
GACC-30, a reverse primer HB-344-R20 (nts 344-325): 50-
AGGTTGGTGAGTGATTGGAG-30, and Taq Man probe HB-242-S26FT
(nts 242e267): 50-CAGAGTCTACACTCGTGGTGGACTTC-30.
2.7. Generation of chimeric mouse with tupaia liver
Primary tupaia hepatocytes from 3-week-old tupaia (primary
tupaia hepatocytes #2) were transplanted into the liver of cDNA-
uPA/SCID mice (5.0  105 cells/animal) via the spleen [14]. At 8
weeks post transplantation, sera were collected to measure the
tupaia albumin level.
2.8. Histological analysis
Liver tissues of the chimeric mice were ﬁxed with 10%
phosphate-buffered formalin and embedded in parafﬁn. The sam-
ples were then sectioned and stained with hematoxylin and eosin.
2.9. Evaluation of the replacement of tupaia hepatocytes
Hepatocytes were isolated from the chimeric mice by using a
two-step collagenase perfusion method as described above.
Thereafter, the hepatocytes were incubated with anti-mouse he-
patocyte-speciﬁc antibodies (IgG, IY0266Z, Institute of Immu-
nology, Tokyo, Japan) labeled with Dynabeads (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) for 30 min on ice. Only mouse cells
were labeled with the beads. The number of viable tupaia cells
without beads and viable mouse hepatocytes with beads were
counted by the trypan blue exclusion test, and the ratio of tupaia
hepatocytes to that of the mouse hepatocytes was calculated [12].
2.10. Measurement of serum albumin level
The albumin levels of the sera from the chimeric mice with
tupaia hepatocytes were measured using the monkey albumin
ELISA kit (Immunology Consultants Laboratory, Inc., Portland, OR,
USA) according to the manufacturer's instructions.
2.11. HBV infection to chimeric mouse with tupaia hepatocytes
Fourteen-week-old (11 weeks after transplantation) chimeric
mice with tupaia hepatocytes were inoculated intravenously with
1.0  106 viral DNA copies of HBV. Sera were collected every 2
weeks for 10 weeks and stored at 80 C until use.
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Fig. 1. (A) Procedure for the isolation of tupaia hepatocytes. (B) Morphology of the tupaia hepatocytes at 1 day after seeding. Bar, 50 mm (C) Viral DNA titer in the culture ﬂuid of
tupaia or human hepatocytes infected with HBV. Error bars represent standard deviation. Asterisks represent signiﬁcant difference between tupaia hepatocytes and human he-
patocytes. (D) Viral DNA in tupaia hepatocytes infected with HBV.
T. Sanada et al. / Biochemical and Biophysical Research Communications 469 (2016) 229e235 2312.12. HBV infection to tupaia
One-year-old tupaias (n ¼ 14) were inoculated intravenously
with 1.0  106 viral DNA copies of HBV. Sera were collected every 2
weeks and stored at 80 C until use.2.13. Measurement of serum alanine aminotransferase (ALT)
activity
Serum ALT activity in tupaia was determined using Trans-
aminase CII-test Wako (Wako Pure Chemical Industries, Osaka,
Japan).2.14. HBs quantiﬁcation
Serum HBsAg levels in tupaia were measured by the two-step
sandwich assay principle with a fully automated chemilumines-
cent enzyme immunoassay system (Lumipulse G 1200, Fujirebio,
Tokyo, Japan) [15].2.15. Statistical analyses
Student's t-test was used to conduct statistical analyses of the
data. p values lower than 0.05 were considered to be signiﬁcant.3. Results
3.1. HBV-DNA levels in primary tupaia hepatocytes and primary
human hepatocytes
To evaluate the ability of tupaia hepatocytes to support HBV
infection, we isolated tupaia primary hepatocytes (Fig. 1A). Isolated
cells exhibited epithelial cell morphology and distinctly round
nuclei with prominent nucleoli, which is typical of a hepatocyte
(Fig. 1B). We infected HBV genotypes A, B, and C to primary tupaia
hepatocytes and primary human hepatocytes, and measured HBV-
DNA level in culture supernatant at 2, 7, and 12 dpi (Fig. 1C) and in
the hepatocytes at 2, 7, and 21 dpi (Fig. 1D). All HBV genotypes
infected and propagated in both tupaia hepatocytes #1, #2, and
primary human hepatocytes. In culture supernatants at 12 dpi, the
viral DNA titer of genotypes B and C in tupaia hepatocytes were
equally or signiﬁcantly higher than those in human hepatocytes
(Fig. 1C). The genotype A in the viral titers in both tupaia hepato-
cytes was signiﬁcantly lower than that in human hepatocytes at 12
dpi. The HBV-DNA levels in tupaia hepatocytes also increased
gradually and reached 103-106 copies/mg of DNA at 21 dpi (Fig. 1D).
3.2. Replacement of chimeric mice hepatocytes with tupaia
hepatocytes and HBV infection
To evaluate the ability of tupaia hepatocytes to support HBV
propagation in vivo, we next transplanted primary tupaia hepato-
cytes #2 to cDNA-uPA/SCID mice (Fig. 2A), and carried out HBV
T. Sanada et al. / Biochemical and Biophysical Research Communications 469 (2016) 229e235232infection after 11 weeks. After transplantation, the mice survived at
least 5 months in spite of the presence of the uPA gene. No gross
pathology was observed like white liver disease due to hepatocyte
injury (Fig. 2B). Hematoxylin and eosin staining showed that the
transplanted hepatocytes engrafted into the liver were organized at
the liver plate (Fig. 2C). The efﬁciency of the replacement was
evaluated bymeasuring the serum albumin levels in chimeric mice.
ELISA showed the tupaia serum albumin levels, but not mouse
serum albumin levels (Fig. 2D). At 8 weeks post-transplantation,
the OD values of the chimeric mouse sera were similar or more
than those of tupaia. The tupaia hepatocytes replaced the chimeric
mouse hepatocytes at a rate of 96.2% (#5) and 97.6% (#8) (Fig. 2E).
These data show that tupaia hepatocytes had sufﬁciently replaced
the chimeric mouse hepatocytes.
To assess the growth of HBV in the chimeric mice with tupaia
hepatocytes, we infected chimeric mice with HBV (HBV genotypesC
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notype J showed HBV-DNA positive with high frequency, especially
in the early phase of HBV infection. For detailed growth charac-
terization, the ALT level, which is the marker of liver damage, and
the HBsAg levels were analyzed (Fig. 3B). Similar to the kinetics of
HBV-DNA, HBsAg was detected persistently for 14 weeks. At 16e18
wpi, the ALT level increased abruptly, after which the HBV-DNA and
HBsAg were undetectable.Ta
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e.4. Discussion
The lack of efﬁcient experimental animal models that are sus-
ceptible to HBV infection has hampered the study of HBV patho-
genesis. HBV infection in tupaia has shown to result in hepatitis and
persistent infection like that in humans [16,17]. Therefore, tupaia is
expected to be a suitable animal model for HBV infection. However,
the infection mode in tupaia and the host response against HBV
infection is unknown.
Several studies have shown that chimeric mouse with human-
ized liver based on uPA/SCID supports hepatitis infections caused
by HBV and HCV [9,18]. This mouse is immune deﬁcient and thus a
suitable host to address the response to viral infection in hepato-
cytes. To address the tupaia response in hepatocytes precisely, we
developed a chimeric mouse with tupaia hepatocytes. We
T. Sanada et al. / Biochemical and Biophysical Research Communications 469 (2016) 229e235234succeeded in developing a chimeric mousewith tupaia hepatocytes
with high replacement with tupaia hepatocytes (>95%), thus
making it a powerful tool to analyze host innate immunity response
against various pathogens and not only HBV. This replacement level
is higher than that previously reported in chimeric mouse with
tupaia liver [19] and same level as chimeric mouse with humanized
mouse based on cDNA-uPA/SCID mouse [14].
In the present study, we examined the ability of tupaia hepa-
tocytes to support HBV infection in vitro and in vivo. Primary tupaia
hepatocytes showed high efﬁciency for HBV replication and
chimeric mice with tupaia hepatocytes produced 104e106 copies/
ml. A previous study showed that after HBV infection, chimeric
mice with humanized liver could support HBV infection efﬁciently
(~1.5  106 copies/ml of serum) [20]. These data indicate that like
human hepatocytes, tupaia hepatocytes can also support HBV
replication. In contrast, the HBV-DNA levels in adult tupaia were
less than 103 copies/ml of serum. The level of HBV replication in
adult tupaia was much lower than that in primary tupaia hepato-
cytes and chimeric mouse with tupaia hepatocytes. This suggests
that the immune system of tupaia may have a critical factor that
suppresses HBV infection. A recent study indicated that TNFa [21]
and IFNg strongly suppressed HBV replication by targeting the
covalently closed circular DNA [22]. The expression levels of these
factors in HBV-infected tupaia and chimeric mice needed to be
compared to analyze the essential factors required for the regula-
tion of HBV replication.
Chronic HBV infection is deﬁned by HBV persistence for more
than 6monthswith detectable HBsAg and HBV titers (>2000 IU/ml)
[23]. In adult tupaia, not all but 1 individual out of 2 (genotype J) or
4 out of 12 tupaias (genotype A) showed chronic HBV infection. In
humans, mother-to-child-transmission is one of themajor routes of
HBV infection, and such infected infants develop chronic HBV
infection [24]. Thus, inoculation in neonatal tupaia may accelerate
the chronic infection rate.
HBV showed different propagation rates in primary tupaia he-
patocytes, chimeric mouse with tupaia hepatocytes, and adult
tupaia. This study shows the differences in the host response to
HBV infection and the mechanism of persistent infection. In addi-
tion, the use of primary hepatocytes and chimeric mouse strongly
highlights the potential of using tupaia animal model for HBV
research. Thus, antiviral therapies can be developed in the future
using this tupaia model by analyzing the expression proﬁle of the
factors regulating the HBV infection and by performing a compre-
hensive analysis of the HBV genome.
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